Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ: FULC )

3.960 -0.020 (-0.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Fulcrum Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Inc. (NASDAQ: FULC) Near the Top of Equities by Percentage Gain on 11/7
Via Investor Brand Network
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
NASDAQ:FULC Long Term Investor Alert: Investigation of Potential Wrongdoing at Fulcrum Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 09/14/2023 -- Certain directors of Fulcrum Therapeutics, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food... 
Via FinancialNewsMedia
Exposures Product Safety
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Enrolled 260 patients; topline data expected in the fourth quarter of 2024 
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Inc. (NASDAQ: FULC) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Appoints Chief Financial Officer
— Alan A. Musso appointed as CFO effective August 7, 2023 — 
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
CAMP4 Therapeutics grants exclusive rights to advance novel therapies for Diamond-Blackfan Anemia 
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fulcrum Therapeutics, Inc. (FULC)
From The Law Offices of Frank R. Cruz
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edgio, Fulcrum, adidas, and Spirit AeroSystems and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
FULC DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important June 27 Deadline in Securities Class Action - FULC
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
FULCRUM DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important June 27 Deadline in Securities Class Action - FULC
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Upcoming Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fulcrum Therapeutics, Inc. (FULC) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Upcoming Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fulcrum Therapeutics, Inc. (FULC) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
FULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fulcrum Therapeutics, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.